Keywords
How to Cite
Abstract
Aim. To reveal the characteristic features of tumor growth after orthotopic (OT) and intraperitoneal transplantation (IT) of high-grade syngeneic ovarian carcinoma.
Material and methods. Twenty mature female Wistar rats were randomized into two groups of ten each. The first group – animals underwent OT of ovarian carcinoma (4,3×106 cells) under the membrane of the bursa of the left and right ovaries; the second group – animals underwent IT of the tumor (4,3×107 cells). The endpoints of the study included an assessment of the overall survival (OS) of rats in two groups, determination of the peritoneal cancer index (PCI) on autopsy, and ascites weight. Autopsy material was histologically assessed analysis by light microscopy after standard staining. Cytological examination of ascitic fluid was carried out.
Results. Median OS was 29 days and 21 days in the OT and IT groups, respectively (log-rank test, P = 0.0276). Autopsy did not reveal significant differences in total PCI (12.6 vs 13.6 in the OT and IT groups, respectively) and ascites weight (78.0 g in the OT vs 65.8 g in the IT group). The method of transplantation did not affect the tumor grafting, histological characteristics, the nature of intraperitoneal spread and the ascites volume. It should be noted that there was a greater volume of tumor lesions in the organs of the reproductive system of rats (ovaries, uterus with horns, paragonadal fat pad) in the OT group.
Conclusion. Both methods of transplantation allow to reproduce the advanced stages (III-IV stages) of epithelial ovarian carcinoma in women. OT requires more time and operating conditions. OT and IT can be used to solve various problems in fundamental and routine preclinical cancer research.
References
Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
Momenimovahed Z., Tiznobaik A., Taheri S. et al Ovarian cancer in the world: epidemiology and risk factors. Int. J. Womens Health. 2019;11:287–299. doi:10.2147/IJWH.S197604.
Reid B.M., Permuth J.B., Sellers T.A. Epidemiology of ovarian cancer: a review. Cancer Biol. Med. 2017;14(1):9–32.
van Baal J.O.A.M., van Noorden C.J.F., Nieuwland R, et al. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. J. Histochem. Cytochem. 2018; 66(2):67–83. doi:10.1369/0022155417742897.
Helderman R.F.C.P.A., Löke D.R., Kok H.P. et al. Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Сancers (Basel). 2019;11(1):78. doi:10.3390/cancers11010078.
Fredrickson T.N. Ovarian tumors of the hen. Environ. Health Perspect. 1987;73:35‐51. doi:10.1289/ehp.877335.
Kuhn E., Tisato V., Rimondi E. et al. Current Preclinical Models of Ovarian Cancer. J. Carcinog. Mutagen. 2015;6:2.
Cooper T.K., Gabrielson K.L. Spontaneous lesions in the reproductive tract and mammary gland of female non-human primates. Birth Defects Res. B. Dev. Reprod. Toxicol. 2007;80(2):149‐170. doi:10.1002/bdrb.20105.
Krarup T. Oocyte destruction and ovarian tumorigenesis after direct application of a chemical carcinogen (9:0-dimethyl-1:2-benzanthrene) to the mouse ovary. Int. J. Cancer. 1969;4(1):61‐75. doi:10.1002/ijc.2910040109.
Toth B. Susceptibility of guinea pigs to chemical carcinogens: 7,12-Dimethylbenz(a)anthracene and urethane. Cancer Res. 1970;30(10): 2583‐2589.
Tunca J.C., Ertürk E., Ertürk E. et al. Chemical induction of ovarian tumors in rats. Gynecol. Oncol. 1985;21(1):54‐64. doi:10.1016/0090-8258(85)90232-x.
Nishida T., Sugiyama T., Katabuchi H. et al. Histologic origin of rat ovarian cancer induced by direct application of 7,12-dimethylbenz(a)anthracene. Nihon Sanka Fujinka Gakkai Zasshi. 1986;38(4):570‐574.
Connolly D.C., Bao R., Nikitin A.Y., et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 2003;63(6): 1389‐1397.
Kim J., Coffey D.M., Creighton C.J. et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl. Acad. Sci. U S A. 2012;109(10):3921‐3926. doi:10.1073/pnas.1117135109.
Perets R., Wyant G.A., Muto K.W. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell. 2013;24(6):751‐765. doi:10.1016/j.ccr.2013.10.013.
Hernandez L., Kim M.K., Lyle L.T. et al. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol. Oncol. 2016;142(2):332‐340. doi:10.1016/j.ygyno.2016.05.028.
Hallas-Potts A., Dawson J.C., Herrington C.S. Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas. Sci. Rep. 2019;9(1):5515. doi: 10.1038/s41598-019-41941-4.
Fu X., Hoffman R.M. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 1993;13(2):283‐286.
Wu J., Zheng Y., Tian Q. et al. Establishment of patient-derived xenograft model in ovarian cancer and its influence factors analysis. J. Obstet. Gynaecol. Res. 2019;45(10): 2062‐2073. doi:10.1111/jog.14054.
Погосянц, Е.Е., Пригожина Е.Л., Еголина Н.А. Перевиваемая асцитная опухоль яичника крысы (штамм ОЯ). Вопросы онкологии. 1962;8(11):29-36 [Pogosyants, E.E., Prigozhina E.L., Egolina N.A. Perevivaemaya astsitnaya opukhol' yaichnika krysy (shtamm OYa). Vopr. Oncol. 1962;8(11):29-36 (In Russ.)].
Wilkinson-Ryan I., Pham M.M., Sergent P. et al. A Syngeneic Mouse Model of Epithelial Ovarian Cancer Port Site Metastases. Transl. Oncol. 2019; 12(1):62‐68. doi:10.1016/j.tranon.2018.08.020.
McCloskey C.W., Goldberg R.L., Carter L.E. et al. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. Front. Oncol. 2014;4:53. doi:10.3389/fonc.2014.00053.
Scott C.L., Mackay H.J., Haluska P. Jr. Patient-derived xenograft models in gynecologic malignancies. Am. Soc. Clin. Oncol. Educ. Book. 2014:e258‐e266. doi:10.14694/EdBook_AM.2014.34.e258.
Муразов Я.Г., Нюганен А.О., Артемьева А.С. Экспериментальное моделирование карциномы яичника. Лабораторные животные для научных исследований. 2020;3. doi.org/10.29296/2618723X-2020-03-05 [Murazov Ia.G., Niuganen A.O., Artemyeva A.S. Experimental modeling of ovarian carcinoma. Laboratory Animals for Science. 2020;3. doi.org/10.29296/2618723X-2020-03-05 (In Russ.)].
Magnotti E., Marasco W.A. The latest animal models of ovarian cancer for novel drug discovery. Expert Opin. Drug Discov. 2018;13(3):249-257. doi:10.1080/17460441.2018.1426567.
Yoshida Y., Kamitani N., Sasaki H. et al. Establishment of a liver metastatic model of human ovarian cancer. Anticancer Res. 1998;18(1A):327-331.
Klaver Y.L., Hendriks T., Lomme R.M. et al. Intraoperative hyperthermic IP CT after CRS cytoreductive surgery for peritoneal carcinomatosis in an experimental model. Br. J. Surg. 2010. 97(12):1874-1880. doi: 10.1002/bjs.7249.
Shaw T.J., Senterman M.K., Dawson K. et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 2004; 10(6):1032-1042. doi:10.1016/j.ymthe.2004.08.013.
Preston C.C., Goode E.L., Hartmann L.C. et al. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011;3(4):539‐556. doi:10.2217/imt.11.20.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2021